Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (211-220 of 238) with videos related to

Pageof 24
Sort By:
British Journal of Clinical Pharmacology|October 13, 2016
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949Anna K Stalder, Dominik Lott, Daniel S Strasser, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 19, 2021
Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humansChristine Huynh, Janneke M Brussee, Laetitia Pouzol, et al.
Clinical Pharmacology and Therapeutics|September 6, 2006
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patientsPatricia N Sidharta, Frank D Wagner, Holger Bohnemeier, et al.
Journal of Sleep Research|January 8, 2021
Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary diseaseMarie-Laure Boof, Jasper Dingemanse, Mareile Brunke, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2014
Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjectsLi Young Ahn, Sung Eun Kim, SoJeong Yi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2004
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRDLutz Liefeldt, Paul L M van Giersbergen, Jasper Dingemanse, et al.
Frontiers in Pharmacology|April 18, 2022
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: <i>In Vitro</i>, Preclinical, and Clinical DataChristine Huynh, Swen Seeland, Jerome Segrestaa, et al.
Current Drug Metabolism|February 8, 2019
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass SpectrometryClemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Clinical Pharmacology and Therapeutics|April 18, 2018
Assessment of Peripheral Serotonin Synthesis Using Stable Isotope-Labeled TryptophanMartine Gehin, Richard W D Welford, Marco Garzotti, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 2, 2014
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramineHans G Cruz, Justin L Hay, Petra Hoever, et al.
Pageof 24

Showing results (211-220 of 238) with videos related to

Sort By:
Pageof 24
British Journal of Clinical Pharmacology|October 13, 2016
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949Anna K Stalder, Dominik Lott, Daniel S Strasser, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 19, 2021
Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humansChristine Huynh, Janneke M Brussee, Laetitia Pouzol, et al.
Clinical Pharmacology and Therapeutics|September 6, 2006
Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patientsPatricia N Sidharta, Frank D Wagner, Holger Bohnemeier, et al.
Journal of Sleep Research|January 8, 2021
Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary diseaseMarie-Laure Boof, Jasper Dingemanse, Mareile Brunke, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 8, 2014
Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjectsLi Young Ahn, Sung Eun Kim, SoJeong Yi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2004
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRDLutz Liefeldt, Paul L M van Giersbergen, Jasper Dingemanse, et al.
Frontiers in Pharmacology|April 18, 2022
Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: <i>In Vitro</i>, Preclinical, and Clinical DataChristine Huynh, Swen Seeland, Jerome Segrestaa, et al.
Current Drug Metabolism|February 8, 2019
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass SpectrometryClemens Muehlan, Hartmut Fischer, Dieter Zimmer, et al.
Clinical Pharmacology and Therapeutics|April 18, 2018
Assessment of Peripheral Serotonin Synthesis Using Stable Isotope-Labeled TryptophanMartine Gehin, Richard W D Welford, Marco Garzotti, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 2, 2014
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramineHans G Cruz, Justin L Hay, Petra Hoever, et al.
Pageof 24